Get Magazines for free

Categories

10000 to 4crs in 18 months 1000rs to 50crs 300% returns 75% promoter holdings A 50 bagger A sureshot 5 bagger Analysis Another fraud? Auto ancillaries Bank sector Blind sell Brand plays Broking Bse Nse Buy calls cements Ceramics/tiles Counters I don't like Debt free businesses Delisting candidates demerger bets Disclosure- I own them Domestic consumption plays E-Commerce pick Education Exit at rallies Famous analysts Famous stocks FMCG Footwear future multibaggers Gems andJewellery Hidden gems High conviction ideas High dividend plays High potential small caps High ROE stocks Holding companies Hotel sector How they looted you.. Indian stock market Infrastructure sector Interesting Microcaps IT KPO Landbank plays largecap ideas Less than 5 PE stocks Liquor Logistics Market lessons Market outlook for 2013 and 2014 Market underperformers Meeting with the CEO Metals Monopoly businesses My 5 baggers My Favourite counters My paid stock recommendations My stock picking techniques nse bse tips Oil exploration Operator calls Paints Penny stock outlook penny stock updates Pharma sector Poultry stocks PSU Publicity freaks Real estate Renewable energy plays Safe bets Sell recommendations Share market Live shipping stocks short term call SOTP plays stock tips stock under 10rs Stocks to watch out for Strong bonus candidates Takeover candidates TATA product tea Textiles The 13 bagger The 45 bagger Trading companies Transformers Turnaround bets Tyres Uncertain/Risky business models Unique businesses

Search This Blog(Over 800 companies covered in the blog).

Please note

Note: The artciles are not research reports but assimilation of information available on public domain and it should not be treated as a research report.

Registration status with SEBI: I am not registered with SEBI under the (Research Analyst) regulations 2014 and as per clarifications provided by SEBI: “Any person who makes recommendation or offers an opinion concerning securities or public offers only through public media is not required to obtain registration as research analyst under RA Regulations”

Disclosure: It is safe to assume that I might have the dkiscussed companies in my portfolio and hence my point of view can be biased.Readers should consult registered consultants before making any investments
.

Archives : Old artciles

Thursday, December 10, 2009

Smruthi organics Ltd:Buy/sell/hold,growth prospects and recomendation,news and results,target price and analysis

Scripscan:Smruthi organics Ltd
Code:590046
cmp:66

Story:Smruthi organics Ltd (SOL) is engaged in the manufacturing and marketing of Active Pharmaceutical Ingredients (API). SOL also manufactures some drug intermediates, photography developing and specialty chemicals. SOL has two manufacturingsites: Unit I - MIDC Akkalkot Road and Unit II MIDC Chincholi (both near Solapur Maharashtra). Manufacturing of API is done at Unit II, while Unit I acts as a supporting unit to Unit II, engaged in manufacturing intermediates. Unit II is approved by the USFDA in 2007 and also certified by EU regulatory authorities for Norfloxacin, Metformin HCI and Carbidopa.SOL has established marketing relationships in both EU and US markets with top global pharmaceutical companies. Although majority of the customers operate in the generic space, SOL also does business with large innovator Pharma companies. SOL has entered into long term (up to 5 years) multi product contracts with numerous clients and has secured substantial business.Owing to greater demand of several products, SOL plans to file 3 more DMFs (Drug master Files) each in US and EU in FY10.Norfloxacin, Metformin Hcl and Ciprofloaxacin are three of its large products in FY09 accounting for 69% of its sales.With consolidation in the international pharmaceutical industry and growth in demand for lifestyle related products, the demand for API is increasing multifold. SOL can independently or in conjunction with the customer develop optimized synthesis process, perform scale-up and process validations, compile DMF and provide the customer with regulatory support for finished formulation dossier registration. SOL has marketing relationships in both US and EU markets with top global pharmaceutical companies. Although majority of the customers operate in the generic space, it also has business with large innovator Pharma companies. Its main focus going forward is on contract manufacturing with 75-80% coming from exports (incl deemed exports)in FY10 and more than 90% in FY11 of the total revenues.At the CMP the stock is trading at 16.7x FY09 EPS of Rs.4.0 and 10.8x FY10E EPS of Rs.13.4 (quick estimates). With all approvals and facilities in place and expected new launches, SOL’s sales and profitability are set to improve over the next few years. The first hint of this is available in its Q2FY10 results, where it benefited out of approvals received for some of its products for which exports have begun. We feel that the stock can be bought at the CMP and added on dips to Rs.53-57 band for sequential targets of Rs.81 and Rs.92 over the next few quarters.

Source:Hdfc sec

Important Disclaimer&Privacy policy

This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
 
x

Subscription to Arunthestocksguru

Enter your email address:

Delivered by FeedBurner